Johnson & Johnson has recently come under fire in the form of multiple lawsuits for their medications and medical devices, but Xarelto is proving to be even more of a liability for the company. Xarelto, generic name rivaroxaban, is a medication designed to prevent a particular type of blood clot known as deep-vein thrombosis (DVT), which can cause pulmonary embolisms, affecting the lungs. Xarelto has also been used to lower stroke risk caused by blood clots. Xarelto is currently the subject of numerous lawsuits due to improper safety information regarding uncontrolled bleeding and spinal blood clots. Over fifteen thousand lawsuits have been filed against the drug’s manufacturer to date.
While Xarelto was originally marketed as a better alternative to Warfarin with greater efficacy and safety, plaintiffs claim that important safety information was withheld from the public, and that Johnson & Johnson did not take the proper safety precautions to prevent bleeding in certain patients. Users of the medication were informed that they did not require blood monitoring because of the supposed reduced risk of bleeding. As many as 14,000 patients have filed cases in Louisiana, with another 1,000 in Pennsylvania. The lawsuits center around misleading marketing materials, which increased risk of injury and illness for users of the medication.
Warfarin users need to have their blood monitored regularly by their doctor in order to be prescribed the correct dosage – a process that can be time-consuming and inconvenient, but ensures the patient’s safety when using the medication. Warfarin also provides an antidote that can reverse the effects of the medication in the event that too large a dose is consumed, preventing negative impact on patients’ health. Xarelto was advertised as not requiring either blood monitoring or an antidote, making it seem much more convenient and less intrusive.
Johnson & Johnson’s failure to warn its customers of the hazards associated with using Xarelto are proving to be a strong case against the company. Along with the defective hip replacements, medications, and other faulty products the manufacturer has produced over the past year, things are not shaping up in Johnson & Johnson’s favor for the coming months. In the coming lawsuits, a jury will decide to what extent the company’s leadership is responsible for damages suffered by its patients, with some victims requiring multiple blood transfusions following antidote administration in order to survive the illness caused by Xarelto.
If you have been injured as a result of using Xarelto or similar medication, the Philadelphia medical product liability lawyers at Brookman, Rosenberg, Brown & Sandler can help. Providing high quality representation for victims of faulty medical devices to clients across the greater Philadelphia area, Brookman, Rosenberg Brown & Sandler bring years of experience and carefully constructed cases to the courtroom. Contact us online or call 215-569-4000 or 800-369-0899 today to arrange a free consultation.